ADVANCED SOLID TUMOR (PHASE 1)
Clinical trials for ADVANCED SOLID TUMOR (PHASE 1) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMOR (PHASE 1) trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMOR (PHASE 1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Matched conditions: ADVANCED SOLID TUMOR (PHASE 1)
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill hopes to fight advanced cancers when other treatments fail
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called EP102 in people with advanced solid tumors who have no other treatment options. The main goals are to find the safest dose and understand side effects. About 48 participants with specific cancer types will take the dru…
Matched conditions: ADVANCED SOLID TUMOR (PHASE 1)
Phase: PHASE1 • Sponsor: Epics Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Matched conditions: ADVANCED SOLID TUMOR (PHASE 1)
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…
Matched conditions: ADVANCED SOLID TUMOR (PHASE 1)
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC